| Name | BMS-929075 |
|---|---|
| Synonyms |
4-Fluoro-2-(4-fluorophenyl)-N-methyl-5-(2-methyl-5-{[1-(2-pyrimidinyl)cyclopropyl]carbamoyl}phenyl)-1-benzofuran-3-carboxamide
MFCD31556637 BMS-929075 3-Benzofurancarboxamide, 4-fluoro-2-(4-fluorophenyl)-N-methyl-5-[2-methyl-5-[[[1-(2-pyrimidinyl)cyclopropyl]amino]carbonyl]phenyl]- |
| Description | A highly potent, selective, orally bioavailable HCV NS5B polymerase inhibitor with IC50 of 9, 4, and 18 nM for GT1a, GT1b, and GT1b-C316N mutant in HCV replicon assay, respectively; possesses excellent pharmacokinetic parameters across preclinical animal species. HCV Infection Phase 1 Clinical |
|---|---|
| References | References 1. Yeung KS, et al. J Med Chem. 2017 May 25;60(10):4369-4385. View Related Products by Target HCV HCV Infection |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 725.5±60.0 °C at 760 mmHg |
| Molecular Formula | C31H24F2N4O3 |
| Molecular Weight | 538.544 |
| Flash Point | 392.6±32.9 °C |
| Exact Mass | 538.181641 |
| LogP | 3.93 |
| Vapour Pressure | 0.0±2.4 mmHg at 25°C |
| Index of Refraction | 1.684 |